Menu Search
Equities

NervGen Pharma Corp

  • Add to watchlist
  • Add to portfolio
  • Add an alert
9UA:MUN

NervGen Pharma Corp

Actions
  • Price (EUR)3.30
  • Today's Change-0.24 / -6.78%
  • Shares traded1.00k
  • 1 Year change+63.37%
  • Beta0.8508
Data delayed at least 15 minutes, as of Feb 06 2026 07:01 GMT.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

NervGen Pharma Corp. is a clinical-stage biotech company. The Company is engaged in developing treatments to promote nervous system repair in the settings of neurotrauma and neurologic disease. NVG-291 is in a Phase 1b/2a clinical trial in spinal cord injury and has undertaken preclinical evaluation of a new development candidate, NVG-300, in models of ischemic stroke, amyotrophic lateral sclerosis (ALS) and spinal cord injury (SCI). Its NVG-291 is a therapeutic peptide targeting nervous system repair.

  • Revenue in CAD (TTM)0.00
  • Net income in CAD-25.82m
  • Incorporated2017
  • Employees10.00
  • Location
    NervGen Pharma CorpSuite 1703 - 595 Burrard StreetVANCOUVER V7X 1J1CanadaCAN
  • Phone+1 (604) 722-5361
  • Fax+1 (604) 722-5361
  • Websitehttps://www.nervgen.com/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.